Compare New Era Energy & Digital Inc. Common Stock (NUAI) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
New Era Energy & Digital Inc. Common Stock vs Spyre Therapeutics Inc. Common Stock — how do they compare? New Era Energy & Digital Inc. Common Stock trades at $3.4 (market cap $518.22M), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 14.5× New Era Energy & Digital Inc. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, New Era Energy & Digital Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold New Era Energy & Digital Inc. Common Stock for 2 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| NUAI | SYRE | |
|---|---|---|
Market Cap | $518.22M | $7.52B |
Volume | 7,267,523 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $8.06 | $108.92 |
52-Week Low | $2.37 | $22.18 |
Typical Hold Time | 2 Days | 0 Days |
Enterprise Value | $463.57M | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUAI trades at $4.29, down 1.15% today, with a bearish technical signal despite recent positive news about a 20-year power deal for its Texas data center project. The company shows severe financial stress with negative margins (-5,985.71% net income margin) and consecutive quarterly losses, though analyst consensus remains bullish with a $10.67 price target. Recent institutional interest includes BlackRock's new stake in Q2 2026.
The stock presents high-risk speculation with potential upside if data center development succeeds, but faces substantial execution and funding risks. Current fundamentals are weak, making it suitable only for risk-tolerant investors betting on future project milestones and hyperscaler partnerships.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About New Era Energy & Digital Inc. Common Stock
New Era Energy & Digital develops large-scale data centers in energy-rich U.S. markets for AI training and inference workloads. Its Texas Critical Data Centers project in the Permian Basin combines modular deployment with flexible power solutions.
Read more on NUAI →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
